Go Pro

Craneware (CRW) Competitors

Craneware logo
GBX 1,204 +24.00 (+2.03%)
As of 11:22 AM Eastern

CRW vs. EMIS, INS, KOO, COG, and RENX

Should you buy Craneware stock or one of its competitors? MarketBeat compares Craneware with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Craneware include EMIS Group (EMIS), Instem (INS), Kooth (KOO), Cambridge Cognition (COG), and Renalytix (RENX). These companies are all part of the "health information services" industry.

How does Craneware compare to EMIS Group?

EMIS Group (LON:EMIS) and Craneware (LON:CRW) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

EMIS Group has higher earnings, but lower revenue than Craneware. EMIS Group is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EMIS Group£176.86M0.00£30.48M£0.47N/A
Craneware£211.33M1.95£14.27M£62.9019.14

In the previous week, Craneware's average media sentiment score of 0.34 beat EMIS Group's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
EMIS Group Neutral
Craneware Neutral

105.6% of EMIS Group shares are held by institutional investors. Comparatively, 36.5% of Craneware shares are held by institutional investors. 3.6% of EMIS Group shares are held by company insiders. Comparatively, 10.3% of Craneware shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

EMIS Group has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, Craneware has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

EMIS Group pays an annual dividend of GBX 42 per share. Craneware pays an annual dividend of GBX 41.96 per share and has a dividend yield of 3.5%. EMIS Group pays out 8,936.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Craneware pays out 66.7% of its earnings in the form of a dividend. Craneware is clearly the better dividend stock, given its higher yield and lower payout ratio.

EMIS Group has a net margin of 17.23% compared to Craneware's net margin of 10.63%. EMIS Group's return on equity of 23.17% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
EMIS Group17.23% 23.17% 7.99%
Craneware 10.63%6.65%2.28%

Craneware has a consensus target price of GBX 2,222.75, suggesting a potential upside of 84.61%. Given Craneware's stronger consensus rating and higher possible upside, analysts clearly believe Craneware is more favorable than EMIS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EMIS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Craneware beats EMIS Group on 10 of the 16 factors compared between the two stocks.

How does Craneware compare to Instem?

Instem (LON:INS) and Craneware (LON:CRW) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Craneware's average media sentiment score of 0.34 beat Instem's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
Instem Neutral
Craneware Neutral

Instem has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Craneware has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

65.9% of Instem shares are held by institutional investors. Comparatively, 36.5% of Craneware shares are held by institutional investors. 30.0% of Instem shares are held by insiders. Comparatively, 10.3% of Craneware shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Craneware has a consensus price target of GBX 2,222.75, suggesting a potential upside of 84.61%. Given Craneware's stronger consensus rating and higher probable upside, analysts plainly believe Craneware is more favorable than Instem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Craneware has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instem£61.63M0.00£3.34M£0.14N/A
Craneware£211.33M1.95£14.27M£62.9019.14

Craneware has a net margin of 10.63% compared to Instem's net margin of 5.50%. Craneware's return on equity of 6.65% beat Instem's return on equity.

Company Net Margins Return on Equity Return on Assets
Instem5.50% 6.35% 4.62%
Craneware 10.63%6.65%2.28%

Summary

Craneware beats Instem on 9 of the 14 factors compared between the two stocks.

How does Craneware compare to Kooth?

Kooth (LON:KOO) and Craneware (LON:CRW) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Kooth has a beta of 1.299, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Craneware has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Craneware has a net margin of 10.63% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth4.12% 8.84% 10.12%
Craneware 10.63%6.65%2.28%

Craneware has higher revenue and earnings than Kooth. Craneware is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£63.29M0.89£4.00M£7.0022.23
Craneware£211.33M1.95£14.27M£62.9019.14

21.0% of Kooth shares are held by institutional investors. Comparatively, 36.5% of Craneware shares are held by institutional investors. 30.4% of Kooth shares are held by insiders. Comparatively, 10.3% of Craneware shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kooth currently has a consensus target price of GBX 330, suggesting a potential upside of 112.03%. Craneware has a consensus target price of GBX 2,222.75, suggesting a potential upside of 84.61%. Given Kooth's higher probable upside, equities analysts clearly believe Kooth is more favorable than Craneware.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Craneware's average media sentiment score of 0.34 beat Kooth's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
Kooth Neutral
Craneware Neutral

Summary

Craneware beats Kooth on 8 of the 14 factors compared between the two stocks.

How does Craneware compare to Cambridge Cognition?

Craneware (LON:CRW) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Craneware has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.804, suggesting that its share price is 20% less volatile than the broader market.

Craneware currently has a consensus price target of GBX 2,222.75, indicating a potential upside of 84.61%. Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 74.86%. Given Craneware's higher possible upside, analysts plainly believe Craneware is more favorable than Cambridge Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Craneware's average media sentiment score of 0.34 beat Cambridge Cognition's score of 0.00 indicating that Craneware is being referred to more favorably in the media.

Company Overall Sentiment
Craneware Neutral
Cambridge Cognition Neutral

Craneware has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£211.33M1.95£14.27M£62.9019.14
Cambridge Cognition£9.40M1.83-£1.58M-£3.90N/A

36.5% of Craneware shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 10.3% of Craneware shares are held by insiders. Comparatively, 2.8% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Craneware has a net margin of 10.63% compared to Cambridge Cognition's net margin of -17.82%. Craneware's return on equity of 6.65% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware10.63% 6.65% 2.28%
Cambridge Cognition -17.82%-62.89%-0.30%

Summary

Craneware beats Cambridge Cognition on 13 of the 14 factors compared between the two stocks.

How does Craneware compare to Renalytix?

Renalytix (LON:RENX) and Craneware (LON:CRW) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, Craneware's average media sentiment score of 0.34 beat Renalytix's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
Renalytix Neutral
Craneware Neutral

Renalytix has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Craneware has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 36.5% of Craneware shares are owned by institutional investors. 5.1% of Renalytix shares are owned by insiders. Comparatively, 10.3% of Craneware shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Craneware has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M3.71-£109.93M-£4.00N/A
Craneware£211.33M1.95£14.27M£62.9019.14

Craneware has a net margin of 10.63% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-506.25% 675.00% -93.54%
Craneware 10.63%6.65%2.28%

Craneware has a consensus target price of GBX 2,222.75, suggesting a potential upside of 84.61%. Given Craneware's stronger consensus rating and higher possible upside, analysts plainly believe Craneware is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Craneware beats Renalytix on 12 of the 15 factors compared between the two stocks.

Get Craneware News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRW vs. The Competition

MetricCranewareHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£412.21M£910.86M£7.05B£2.82B
Dividend Yield2.92%6.06%2.67%6.15%
P/E Ratio19.14301.1927.19367.99
Price / Sales1.95139.89490.9183,997.84
Price / Cash14.7247.1426.3927.89
Price / Book1.297.8510.267.31
Net Income£14.27M-£22.78M£3.60B£5.89B
7 Day Performance2.73%0.15%-2.22%0.30%
1 Month Performance-13.51%-2.41%-3.16%0.31%
1 Year Performance-49.24%-10.69%17.33%67.61%

Craneware Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRW
Craneware
4.1659 of 5 stars
GBX 1,204
+2.0%
GBX 2,222.75
+84.6%
-49.7%£412.21M£211.33M19.14734
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
INS
Instem
N/AN/AN/AN/A£199.62M£61.63M5,928.57500
KOO
Kooth
N/AGBX 160
+0.9%
GBX 330
+106.3%
-13.7%£58.04M£63.29M22.86478
COG
Cambridge Cognition
N/AGBX 31.25
-0.8%
GBX 56
+79.2%
-0.7%£16.82M£9.40MN/A80

Related Companies and Tools


This page (LON:CRW) was last updated on 7/28/2026 by MarketBeat.com Staff.
From Our Partners